原研与仿制莫西沙星注射液在治疗社区获得性肺炎中的成本-效果分析

目的:研究原研莫西沙星对比仿制莫西沙星治疗社区获得性肺炎中的有效性和经济性.方法:采用前瞻性研究方法,选取2018年1月—2019年12月收治的85例社区获得性肺炎患者,根据患者治疗意愿分为原研组45例和仿制组40例.均连续给药7d.比较两组患者临床疗效和不良反应发生情况.以治疗总费用为成本,采用成本-效果分析方法评价...

Cost-effectiveness analysis of original andgeneric moxifloxacin injection in the treatment of community acquired pneumonia

OBJECTIVE To explore the efficacy and economics of original and generic moxifloxacin injection in the treatment of community acquired pneumonia(CAP). METHODS For this prospective study,85 CAP patients were selected from January 1,2018 to December 31,2019.They were divided into original group(n=45) and generic group(n=40) according to the patient’s treatment intention.Treatment lasted for 7 days in both groups.Effective rate and occurrence of adverse drug reaction(ADR) were compared between two groups.Cost-effectiveness analysis was performed for evaluating the cost-effectiveness ratio(C/E) and incremental cost-effectiveness ratio(ICER,ΔC/ΔE) of two groups using total cost of treatment.Sensitivity analysis was performed by reducing different cost by 15%. RESULTS Effective rate of two groups was 84.4% and 82.5% respectively.There was no statistical significance(P>0.05).The incidence of drug allergy and abnormal blood glucose was higher in generic group than those in original group.There was no statistical significance(P<0.05).The total cost of original and generic groups was 9648.72 and 8403.11 yuan respectively(P>0.05).C/E of effective rate was 114.32 and 101.86 and ΔC/ΔE of effective rate between original and generic groups 655.58.Sensitivity analysis supported the results of cost-effectiveness analysis. CONCLUSION Original and generic moxifloxacin have a similar efficacy for CAP.However,considering the incidence of adverse reactions and willingness to pay,the economic advantage of generic moxifloxacin is unobvious.